Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04270591 · ClinicalTrials.gov registry record · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
A Phase 1 study of C-Met Exon 14 Mutation, sponsored by Haihe Biopharma Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 183
- Enrollment target
- 20
- Study locations
NCT04270591 is a Phase 1 study of C-Met Exon 14 Mutation that is actively recruiting participants, run by Haihe Biopharma Co.. The registered enrollment target is 183 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04270591, a Phase 1 study of C-Met Exon 14 Mutation, is actively recruiting participants, sponsored by Haihe Biopharma Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 183 participants
- Enrollment target
- 20
- Study locations
Study Summary
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
Conditions Studied
Interventions
- DRUG Glumetinib
Study Locations (20)
Beijing Municipality
- Beijing Cancer Hospital - Beijing
- Beijing Cancer Hospita - Beijing
- Peking Union Medical College Hospital - Beijing
Kentucky
- Norton Cancer Institute - Louisville
- The Oncology Institute of Hope & Innovation - Louisville
Anhui
- Anhui Province Hospital - Hefei
- The Chest Hospital of Anhui Province - Hefei
Hubei
- Hubei Cancer Hospital - Wuhan
- Wuhan Union Hospital - Wuhan
Jiangsu
- Jiangsu Cancer Hospital - Nanjing
- Jiangsu Province People's Hospital - Nanjing
Fujian
- Union Medical College Hospital Affiliated to Fujian Medical University - Fuzhou
Guangdong
- The First Affiliated Hospital of Guangzhou Medical University - Guangzhou
Guangxi
- Cancer Hospital Affiliated to Guangxi Medical University - Nanning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2023-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04270591
The ClinicalTrials.gov registry entry for NCT04270591 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Haihe Biopharma Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with C-Met Exon 14 Mutation appearing as the primary indexed condition, and to 1 intervention - of which Glumetinib is the first listed.
NCT04270591 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Beijing Municipality, Kentucky, Anhui.
Frequently Asked Questions
What is clinical trial NCT04270591 about?
NCT04270591 is a clinical study titled "Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer". Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
What is the current status of trial NCT04270591?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 183 participants. The study started on 2019-07-15. Estimated completion is 2023-12-30.
What conditions does trial NCT04270591 study?
This clinical trial studies the following conditions: C-Met Exon 14 Mutation.
What interventions are being tested in trial NCT04270591?
The interventions under investigation include: Glumetinib (DRUG).
Who is sponsoring clinical trial NCT04270591?
This trial is sponsored by Haihe Biopharma Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04270591 being conducted?
This trial has 20 study locations across Kentucky, Anhui, Beijing Municipality, Fujian, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.